Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.38 -4.8%	$2.85	$2.07 ▼ $4.20	$114.35M	0.34	102,727 shs	224,888 shs
BYSI BeyondSpring	$3.17 +1.9%	$1.88	$0.98 ▼ $3.44	$125.38M	0.07	33,935 shs	1.34 million shs
CRDL Cardiol Therapeutics	$1.24 -6.1%	$1.19	$0.77 ▼ $2.63	$109.10M	1.03	317,575 shs	291,778 shs
MRNS Marinus Pharmaceuticals	$0.55 -0.2%	$0.55	$0.22 ▼ $1.97	$30.32M	1.03	1.83 million shs	260 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	-1.39%	+36.02%	+12.34%	+43.72%
BYSI BeyondSpring	0.00%	+9.89%	+85.01%	+94.38%	+9.51%
CRDL Cardiol Therapeutics	0.00%	-8.33%	+17.86%	+17.86%	-36.54%
MRNS Marinus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-60.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	3.2114 of 5 stars	3.6	5.0	0.0	0.0	1.6	3.3	0.0
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	1.5215 of 5 stars	3.7	2.0	0.0	0.0	0.6	0.0	0.6
MRNS Marinus Pharmaceuticals	2.2288 of 5 stars	3.2	0.0	0.0	4.2	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	166.27% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
CRDL Cardiol Therapeutics	3.40	Buy	$8.67	598.92% Upside
MRNS Marinus Pharmaceuticals	2.40	Hold	$3.92	613.29% Upside

Current Analyst Ratings Breakdown

Latest MRNS, BYSI, ANIX, and CRDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
4/16/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/7/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/26/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/25/2025	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/21/2025	ANIX Anixa Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	518.43	N/A	N/A	$0.46 per share	7.35
BYSI BeyondSpring	$1.75M	73.04	N/A	N/A	($0.37) per share	-8.57
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
MRNS Marinus Pharmaceuticals	$30.99M	0.98	N/A	N/A	$0.31 per share	1.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	7/14/2025 (Estimated)
MRNS Marinus Pharmaceuticals	-$141.40M	-$2.47	N/A	N/A	N/A	-446.48%	-7,831.35%	-120.74%	8/11/2025 (Estimated)

Latest MRNS, BYSI, ANIX, and CRDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/12/2025	Q1 2025	BYSI BeyondSpring	N/A	-$0.06	N/A	$0.11	N/A	N/A
3/31/2025	Q4 2024	CRDL Cardiol Therapeutics	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
MRNS Marinus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
BYSI BeyondSpring	N/A	2.49	2.49
CRDL Cardiol Therapeutics	0.01	3.26	3.26
MRNS Marinus Pharmaceuticals	N/A	1.66	1.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
BYSI BeyondSpring	40.29%
CRDL Cardiol Therapeutics	12.49%
MRNS Marinus Pharmaceuticals	98.80%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
BYSI BeyondSpring	29.31%
CRDL Cardiol Therapeutics	5.25%
MRNS Marinus Pharmaceuticals	5.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
BYSI BeyondSpring	80	40.32 million	28.50 million	Optionable
CRDL Cardiol Therapeutics	20	82.65 million	78.31 million	Not Optionable
MRNS Marinus Pharmaceuticals	110	55.22 million	52.20 million	Optionable

MRNS, BYSI, ANIX, and CRDL Headlines

Recent News About These Companies

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $4.79 Average Target Price from Brokerages

June 10, 2025 | americanbankingnews.com

Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock

February 11, 2025 | msn.com

Marinus Pharmaceuticals director sells shares worth $869

January 24, 2025 | msn.com

Marinus pharmaceuticals director sells shares for $864

January 24, 2025 | msn.com

Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know

January 10, 2025 | zacks.com

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders

January 10, 2025 | stockhouse.com

Marinus Pharmaceuticals Inc (MRNS) Stock: Greater Than Its Current Valuation?

January 7, 2025 | bovnews.com

MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

January 6, 2025 | businesswire.com

Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal

January 4, 2025 | msn.com

Marinus (MRNS) Gets a Hold from Truist Financial

January 4, 2025 | markets.businessinsider.com

Marinus Pharmaceuticals Inc (MRNS) Stock: Beyond the Surface of Its Performance?

January 4, 2025 | bovnews.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Marinus Pharmaceuticals, Inc. Buyout

January 2, 2025 | markets.businessinsider.com

Marinus Pharmaceuticals to be acquired by Immedica for 55c per share

January 1, 2025 | finance.yahoo.com

Marinus Pharmaceuticals Inc (MRNS) Stock: Understanding Its Underlying Value

December 31, 2024 | bovnews.com

Marinus Pharma to Be Acquired by Immedica in $30 Million Deal

December 31, 2024 | marketwatch.com

Immedica to buy rare disease drugmaker Marinus for $151 million

December 31, 2024 | chicagobusiness.com

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

December 31, 2024 | finance.yahoo.com

Immedica to buy Marinus Pharmaceuticals, stock rises 4%

December 31, 2024 | msn.com

Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%

December 30, 2024 | benzinga.com

MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders

December 30, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRNS, BYSI, ANIX, and CRDL Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.38 -0.17 (-4.79%)

Closing price 04:00 PM Eastern

Extended Trading

$3.62 +0.25 (+7.25%)

As of 07:55 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

BeyondSpring NASDAQ:BYSI

$3.17 +0.06 (+1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 +0.19 (+5.96%)

As of 07:53 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Cardiol Therapeutics NASDAQ:CRDL

$1.24 -0.08 (-6.06%)

Closing price 04:00 PM Eastern

Extended Trading

$1.27 +0.03 (+2.82%)

As of 07:46 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Marinus Pharmaceuticals NASDAQ:MRNS

$0.55 0.00 (-0.16%)

As of 02/11/2025

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time